Clin2
NCT07047014Possibly a fitRecruiting

Tenecteplase for medium vessel occlusion stroke (ARTS trial)

Stroke, IschemicMedium Vessel Occlusions

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests the clot-busting drug tenecteplase in people who had a stroke 4.5 to 24 hours ago due to a medium-sized artery blockage. It aims to see if this medication can improve outcomes without needing a procedure to remove the clot.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
596 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • Your stroke symptoms started between 4.5 and 24 hours ago (including wake-up strokes).
  • A CT or MRI scan shows a blockage in a medium-sized brain artery (such as the M2, M3, A1–A3, or P1–P3 segments).
  • You were independent before the stroke (able to do all usual activities).
  • You do not plan to have a clot-removal procedure (endovascular therapy) and have not had recent major surgery or bleeding problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06010628Recruiting· Phase 4
Tenecteplase for stroke 4.5 to 6 hours after onset

This trial tests a medicine called tenecteplase (a clot-buster) for people who have a moderate or severe stroke caused by a clot and can be treated 4.5 to 6 hours after symptoms start. It aims to see if this medicine can help improve recovery.

Shenyang, None Selected
NCT07357987Recruiting· Phase 3
Stroke treatment with tenecteplase via artery

This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.

Beijing, Beijing Municipality
NCT06954155Recruiting· Phase 3
Tenecteplase for stroke treatment 24-72 hours after symptoms start

This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.

Beijing
NCT07253181Recruiting· Phase 3
Stroke clot-busting drug before transfer for artery clearing

This trial tests whether giving a clot-busting drug (tenecteplase) before transferring you to a hospital that can do a procedure to remove the clot improves outcomes for people who had a stroke up to 24 hours earlier. You may qualify if you have a blockage in a large artery in the front of your brain and can still get the procedure.

Beijing, Beijing Municipality
NCT07469293Not yet recruiting· Phase 3
Study of artery-injected tenecteplase for stroke with medium vessel blockage

This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.

Baise City, Guangxi
NCT07302854Recruiting· Phase 2/Phase 3
Clot-busting medicine for medium vessel strokes

This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.

Wuhan, Hubei

Hear when a new Stroke, Ischemic trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.